Lenvatinib and pembrolizumab in patients with advanced uterine cancer
Uterine cancer is one of the few cancers with an increasing incidence and mortality rate in developed countries, which partly reflects the increasing prevalence of obesity and aging of the female population. Despite the fact that uterine cancer is usually diagnosed when lesions have affected only th...
Saved in:
Main Authors: | A. G. Kedrova, A. I. Berishvili, Т. А. Greyan |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2021-01-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/785 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expanding therapeutic opportunities for progressive uterine cancer: clinical experience
by: A. G. Kedrova, et al.
Published: (2022-05-01) -
Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01) -
Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
by: E. A. Khachaturyan, et al.
Published: (2025-05-01) -
The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01) -
Efficacy and safety of combination therapy with lenvatinib and pembrolizumab in elderly patients with advanced endometrial cancer
by: M. V. Volkonskiy, et al.
Published: (2025-05-01)